We investigated the effect that carotid plaque area (CPA) and intima media thickness (IMT) measurements have on risk stratification in 95 patients with intermediate Framingham scores (6% to 19%
The carotid ultrasound tests were performed in an Intersocietal Commission for the Accreditation of Vascular Laboratories-approved diagnostic vascular unit using a 7.5-MHz linear array transducer connected to a Powervision ultrasound device (Toshiba, Inc., Tustin, California). On-screen measurements of IMT 6,7 and CPA 9 were determined as previously described in the literature.
The clinical characteristics and risk assessment results of the 95 intermediate-risk patients are displayed in Tables 1 and 2 , respectively. The median Framingham risk score was 9, the range was 6 to 18, and the 25th and 75th percentiles were 7 and 13, respectively.
The cardiovascular risk status derived from IMT and CPA assessments (using either threshold criterion) differed substantially from the results of the clinical Framingham risk scores (Figures 1 and 2 , respectively). The risk stratum was changed in most patients (Ն63% of cases). IMT and CPA changed the risk stratum in at least 63% and 73% of cases, respectively (Figures 1 and  2) . Further, the IMT and CPA risk assessments differed in most patients (Tables 3 and 4 , respectively). IMT and CPA stratified patients identically in only 42% (literature review) and 38% (internal laboratory data) of cases. However, risk stratification differed by Ͼ1 level (e.g., low risk by IMT vs high risk by CPA) in very few situations (14% to 17% of cases).
• • • Atherosclerosis screening with IMT and CPA changed the risk stratum in most patients deemed as intermediate risk by clinical criteria alone. This result suggests that IMT and CPA may be useful modalities to enhance risk assessment beyond the Framingham risk score. Many patients without known atherosclerotic disease were found to have an abnormal IMT (22% to 35%) or CPA (27% to 40%), thus placing them in the highest-risk category (equivalent to the risk of coronary heart disease).
Established abnormal threshold values for IMT or CPA do not currently exist. Different threshold criteria would probably change the risk assessments. Nevertheless, criteria from 2 different sources produced very similar findings in our study. Additional research is necessary to better define clinically useful CPA and IMT threshold values (e.g., age and risk factor adjusted risk categories) and to determine the longterm clinical outcome of tailoring medical therapy based upon risk assessment modalities. 
